Subtype
Bladder Neoplasm
CI-CAN-00001978Explore in graph →
Non-malignant390 active trials10 approved drugs25 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001978Explore in graph →
Clinical trials
1,702 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05347342 | A Diagnostic for the Early Detection of Bladder Cancer | active not recruiting | — | 173 | Cedars-Sinai Medical CenterOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT07379255 | Evaluation of Postoperative Adjuvant Chemotherapy Efficacy for Bladder Cancer Based on Organoid Technology. | recruiting | — | 266 | Qilu Hospital of Shandong UniversityOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT07379268 | Evaluation of the Efficacy of Anti-HER2 Antibody-Drug Conjugates (ADC) in Locally Advanced or Metastatic Bladder Cancer Based on Organoid Technology. | recruiting | — | 224 | Qilu Hospital of Shandong UniversityOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT07379281 | Evaluating the Efficacy of Neoadjuvant Chemotherapy Drugs Based on Organoid Technology | recruiting | — | 254 | Qilu Hospital of Shandong UniversityOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT02432963 | Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy | active not recruiting | Phase 1 | 11 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT04701918 | Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma | completed | Phase 2 | 9 | Massachusetts General HospitalOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT06818136 | Bladder EpiCheck European Haematuria Study | recruiting | — | 800 | Nucleix Ltd.INDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
| NCT07359235 | Safety, Tolerability, and Preliminary Efficacy of KD01 Via Intravesical Instillation in Bladder Cancer (BC) | recruiting | Phase 1 | 29 | Tongji HospitalOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT04630730 | Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC | active not recruiting | Phase 2 | 46 | Swiss Cancer InstituteOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT05366881 | cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease(CAMPERR) | recruiting | — | 7,000 | Adela, IncINDUSTRY | 1 | Jan 20, 2026 | clinicaltrials |
| NCT05264337 | Lymphedema After Urologic Surgery | recruiting | — | 400 | Vastra Gotaland RegionOTHER_GOV | 1 | Jan 16, 2026 | clinicaltrials |
| NCT07346053 | The Impact of Time-of-day Administration of EV/P on Objective Response Rate in Adults With Advanced Bladder Cancer(Chrono-EVP) | not yet recruiting | Phase 3 | 224 | Guliz OzgunOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT07347132 | Comparison of Pathological Outcome and Recurrence Rate Between En Bloc and Conventional Transurethral Resection of Bladder Tumor | completed | N/A | 116 | Lahore General HospitalOTHER_GOV | 1 | Jan 16, 2026 | clinicaltrials |
| NCT01810757 | Study of Weekly Radiotherapy for Bladder Cancer(HYBRID) | completed | N/A | 65 | Institute of Cancer Research, United KingdomOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT05375903 | A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) | completed | Phase 1 | 51 | UroGen Pharma Ltd.INDUSTRY | 3 | Jan 14, 2026 | clinicaltrials |
| NCT07339761 | Supporting Sexual Health in Bladder Cancer Patients: A Sequential Mixed-Methods Intervention Study(SPICE) | recruiting | N/A | 30 | University of AarhusOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT06305767 | A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005) | active not recruiting | Phase 1 / Phase 2 | 230 | Merck Sharp & Dohme LLCINDUSTRY | 16 | Jan 13, 2026 | clinicaltrials |
| NCT04260802 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers | terminated | Phase 1 / Phase 2 | 73 | Ocellaris Pharma, Inc.INDUSTRY | 1 | Jan 12, 2026 | clinicaltrials |
| NCT05544552 | Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations(SURF301) | active not recruiting | Phase 1 / Phase 2 | 310 | Tyra Biosciences, IncINDUSTRY | 4 | Jan 12, 2026 | clinicaltrials |
| NCT03474107 | A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) | completed | Phase 3 | 608 | Astellas Pharma Global Development, Inc.INDUSTRY | 19 | Jan 9, 2026 | clinicaltrials |
| NCT05656235 | Renal Retention in High Grade Upper Tract Urothelial Cancer | recruiting | Phase 2 | 20 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT05779631 | Multi-parametric MRI in Patients Suspected for Muscle Invasive Bladder Cancer: a New Local Staging Paradigm(BladParadigm) | recruiting | N/A | 360 | Radboud University Medical CenterOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT00871754 | Molecular Analysis Of Bladder Cancer | active not recruiting | — | 5,000 | Lahey ClinicOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT02989584 | A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer | active not recruiting | Phase 1 / Phase 2 | 54 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT03171025 | Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer(NEXT) | active not recruiting | Phase 2 | 200 | University of UtahOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT04897763 | Assessment of Safety, Tolerability, Radiation Dosimetry, Imaging Properties of 89Zr-girentuximab in Patients With NMIBC(PERTINENCE) | completed | Early Phase 1 | 6 | Institut Cancerologie de l'OuestOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT07324798 | Adaptive Radiotherapy for Genitourinary Cancers(SMART-B01) | recruiting | N/A | 60 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT06870253 | Evaluating Bladder CARE™, a New Non-Invasive Urine Test, for Bladder Cancer Detection in Inconclusive Cases | active not recruiting | — | 80 | Pangea Laboratory LLCINDUSTRY | 1 | Jan 6, 2026 | clinicaltrials |
| NCT04553939 | Neoadjuvant Toripalimab in Combination With Gemcitabine Therapy in Cisplatin Ineligible Local Advanved Bladder Cancer | completed | Phase 2 | 50 | Henan Cancer HospitalOTHER_GOV | 1 | Jan 2, 2026 | clinicaltrials |
| NCT05962541 | Vesical Imaging-Reporting and Data System (VI-RADS) Followed by Photodynamic Trans-urethral Resection of Bladder Tumours (PDD-TURBT) to Avoid Secondary Resections (Re-TURBT) in Non-Muscle Invasive Bladder Cancers (NMIBCs)(CUT-less) | recruiting | Phase 4 | 327 | University of Roma La SapienzaOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT06645808 | PET-imaging of Two Vartumabs in Patients With Solid Tumors(VARTUTRACE) | recruiting | Early Phase 1 | 32 | Var2 PharmaceuticalsINDUSTRY | 1 | Dec 29, 2025 | clinicaltrials |
| NCT05519878 | Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers | recruiting | N/A | 224 | City of Hope Medical CenterOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT06022029 | A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.(ON-5001) | recruiting | Phase 1 | 168 | OncoNano Medicine, Inc.INDUSTRY | 2 | Dec 24, 2025 | clinicaltrials |
| NCT07279597 | A Phase II Study of Toripalimab Plus RC48-ADC With Radiotherapy for Bladder Preservation in HER2-Positive Muscle-Invasive Bladder Cancer | not yet recruiting | Phase 2 | 45 | Tongji HospitalOTHER | 0 | Dec 19, 2025 | clinicaltrials |
| NCT02660645 | Blue Light Cystoscopy With Cysview® Registry(BLCCR) | recruiting | — | 4,400 | PhotocureINDUSTRY | 1 | Dec 18, 2025 | clinicaltrials |
| NCT02993900 | Image-Guided Gynecologic Brachytherapy | recruiting | N/A | 54 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT04369560 | Virtual Histology of the Bladder Wall for Bladder Cancer Staging | recruiting | Early Phase 1 | 42 | Jodi MaranchieOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT06263153 | Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy | recruiting | Phase 2 | 24 | Yuanquan YangOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT06129084 | A Study to Compare the Results of FGFR Testing by Either ctDNA Blood Testing or Standard Tumor Tissue Testing | active not recruiting | — | 260 | Bernie EiglOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT06689176 | Chlorhexidine Antiseptic Irrigation of the Bowel Segment During Radical Cystectomy and Urinary Diversion | recruiting | N/A | 23 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT07043543 | Evaluation of the Clinical Utility of Online Adaptive Radiotherapy in Bladder Cancer (BLADAPT-GETUG V11)(BLADAPT) | not yet recruiting | N/A | 120 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT04157985 | Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors | completed | Phase 3 | 161 | Dan ZandbergOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT07259798 | Histopathological Findings in En-Bloc vs Conventional Transurethral Resection of Bladder Tumors. | completed | N/A | 50 | Ain Shams UniversityOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT05726786 | The Role of Preoperative Immunonutrition on Morbidity and Immune Response After Cystectomy (INCyst Trial)(INCyst) | recruiting | Phase 3 | 232 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Dec 9, 2025 | clinicaltrials |
| NCT00872495 | Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer | recruiting | — | 500 | Lahey ClinicOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT06091124 | Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Neuroendocrine Bladder Carcinoma(NEOBLAST) | recruiting | Phase 2 | 22 | RenJi HospitalOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT04501913 | Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes | completed | — | 22 | City of Hope Medical CenterOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT07265414 | DRG Mutations in Prostate Cancer: a Guiding Light for Enhanced Screening and Personalised Therapy | active not recruiting | — | 320 | Istituto Clinico HumanitasOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT02869217 | Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors | active not recruiting | Phase 1 | 22 | University Health Network, TorontoOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT07261592 | Entinostat & Chemotherapy for Locally Advanced or Metastatic Bladder Cancer | not yet recruiting | Phase 1 / Phase 2 | 29 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Dec 3, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Feb 3, 2026source: clinicaltrials